BioMarin plots comeback year, with plans to turn around profits and head back to the FDA with rejected gene therapy
Could this be a comeback year for BioMarin? CEO Jean-Jacques Bienaimé certainly hopes so, as he plans to finally turn the corner on profitability and send the company’s hemophilia gene therapy back to the FDA.
But there are still a few things analysts want to know. Like, what’s going on with the clinical hold on its phenylketonuria gene therapy? And when will the company seek full approval for Voxzogo, its costly achondroplasia drug that got the FDA’s accelerated approval treatment late last year?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.